Tamoxifen, a cornerstone endocrine therapy for estrogen-receptor-positive breast cancer, is bioactivated by CYP2D6 to (Z)-endoxifen, its most active metabolite. A pooled population-pharmacokinetic analysis of six clinical studies (468 patients) quantified the variability of endoxifen exposure, simulated a model-informed precision dosing (MIPD) workflow that would cut the proportion of patients below the proposed 5.97 ng/mL (~16 nM) endoxifen target from ~22% to ~7%, and identified as unresolved future work the validation of the endoxifen exposure–response relationship for breast cancer recurrence and the demonstration in prospective trials that individualized dosing improves clinical outcomes; the same analysis reported that a large interindividual variability in endoxifen formation (~47% CV) remained unexplained by the covariates it identified. These questions remain open: retrospective threshold evidence has been contested by null reanalyses, no determinant set explains the residual variability, and although TDM- and MIPD-based individualization is feasible and has been implemented in single-arm prospective studies with pharmacokinetic endpoints, no randomized trial with recurrence or survival endpoints has been completed (a first phase 3 randomized trial of personalised dose optimisation, POWER, NCT07502820, opened in April 2026 with estimated completion in 2036).

Background

Tamoxifen is a selective estrogen-receptor (ER) modulator used for decades as adjuvant endocrine therapy in ER-positive breast cancer, i.e., tumors whose growth is driven by the estrogen receptor. Tamoxifen is a prodrug: it is converted mainly by the cytochrome P450 enzyme CYP2D6 (a highly polymorphic liver enzyme whose activity differs between individuals because of inherited gene variants) into (Z)-endoxifen, a metabolite roughly 100-fold more potent than tamoxifen itself at blocking estrogen-dependent tumor growth. Because CYP2D6 activity, drug–drug interactions (e.g., with certain antidepressants), and other patient factors vary widely, steady-state endoxifen plasma concentrations span a large range on the standard fixed dose of 20 mg once daily, and about 22% of patients fall below a proposed minimum effective endoxifen concentration of 5.97 ng/mL5.97\ \mathrm{ng/mL} (equivalently about 16 nM). This threshold derives from two retrospective cohort analyses — Madlensky et al. 2011 and Saladores et al. 2015 — which reported ~26% lower breast cancer recurrence and better distant relapse-free survival in patients whose endoxifen exceeded it; it has never been confirmed prospectively. Therapeutic drug monitoring (TDM, dose adjustment guided by measured drug concentrations) and model-informed precision dosing (MIPD, dosing guided by a mathematical pharmacokinetic model of the individual patient) are the two proposed strategies to keep patients above the threshold. The source work (Klopp-Schulze et al. 2020) pooled data from six clinical studies (468 patients, 3,554 concentration observations) into a nonlinear mixed-effects (NLME) population model — a statistical framework that simultaneously estimates typical population pharmacokinetics and partitions variability into interindividual variability (IIV, differences between patients, expressed as coefficient of variation, CV), interoccasion variability (IOV, within-patient variability between dosing periods), and residual error. That analysis quantified that CYP2D6 activity, CYP3A/CYP2D6 drug–drug interactions, and age explain much of the between-occasion variability, but a large IIV in endoxifen formation (47.2% CV) remained unexplained, and simulations showed MIPD (using doses from 5 to 120 mg once daily plus three TDM samples) would reduce the fraction of patients at risk of subtarget endoxifen from 22.2% (standard dosing) to 7.19%. The authors explicitly identified as required future work: (1) establishing the endoxifen exposure–response relationship for breast cancer recurrence and mortality, for which adequately powered prospective trials are needed; (2) prospective demonstration of safety and efficacy of individualized, partly off-label dosing; (3) standardized, validated bioanalytical methods for tamoxifen and endoxifen across centers; and (4) evaluation of the MIPD workflow against standard care in a real-world prospective trial with clinical endpoints. For the exposure–response question the source specifies carefully designed prospective studies jointly assessing pharmacokinetics and clinical endpoints (breast cancer progression/recurrence, adverse drug reactions) and/or an appropriate biomarker (e.g., tumor size, circulating tumor cells, Ki67 antigen over time) in a representative, well-defined tamoxifen patient population, and it records the urgent call made during the exposure–response controversy for a well-designed prospective, randomized clinical trial with sufficient power. The unexplained residual pharmacokinetic variability (39.9% CV on tamoxifen elimination, 47.2% CV on endoxifen formation) remains a feature of the analyzed data. The questions posed below concern the prospective validation of the endoxifen exposure–response relationship and the clinical utility of model-informed precision dosing. A separate open question is whether (Z)-endoxifen supplementation is superior to model-informed precision-dosed tamoxifen with respect to clinical outcomes.

Problem Statement

As stated in the source work and still unresolved: (1) Propose the prospective randomized study design, analysis plan, and power calculation that would test whether achieving endoxifen plasma concentrations above the proposed therapeutic threshold (≥5.97 ng/mL\geq 5.97\ \mathrm{ng/mL}, ~16 nM) reduces breast cancer recurrence and mortality in patients receiving adjuvant tamoxifen, i.e., that would validate or refute the endoxifen exposure–response relationship that individualized-dosing strategies presuppose. The study must jointly assess pharmacokinetics and clinical endpoints (breast cancer progression/recurrence, adverse drug reactions) in a representative, well-defined tamoxifen patient population; a biomarker-only design (e.g., tumor size, circulating tumor cells, Ki67 antigen over time) is not sufficient. (2) Specify the prospective randomized design, analysis plan, and power calculation that would establish whether model-informed precision dosing of tamoxifen — individual dose selection from the population pharmacokinetic model using the patient's CYP2D6 activity score together with endoxifen therapeutic drug monitoring samples — improves outcomes compared with the conventional standard fixed 20 mg once-daily dosing in routine oncology practice, assessed with clinical endpoints and long-term safety monitoring. Each power calculation presupposes a primary clinical endpoint and an assumed effect size (or event rate) grounded in the cited literature. The population pharmacokinetic model, the definition of the CYP2D6 activity score, and the score-to-dose rule are not fixed and must be selected and specified by the solver.

References

  1. Klopp-Schulze L, Mueller-Schoell A, Neven P, Koolen SLW, Mathijssen RHJ, Joerger M, Kloft C (2020) 'Integrated Data Analysis of Six Clinical Studies Points Toward Model-Informed Precision Dosing of Tamoxifen', Frontiers in Pharmacology 11:283. doi:10.3389/fphar.2020.00283, https://doi.org/10.3389/fphar.2020.00283
  2. Madlensky L, Natarajan L, Tchu S, Pu M, Mortimer J, Flatt SW, Nikoloff DM, Hillman G, Fontecha MR, Lawrence HJ, Parker BA, Wu AH, Pierce JP (2011) 'Tamoxifen Metabolite Concentrations, CYP2D6 Genotype, and Breast Cancer Outcomes', Clinical Pharmacology & Therapeutics 89(5):718–725. doi:10.1038/clpt.2011.32, https://doi.org/10.1038/clpt.2011.32
  3. Saladores P, Mürdter T, Eccles D, Chowbay B, Zgheib NK, Winter S, Ganchev B, Eccles B, Gerty S, Tfayli A, Lim JS, Yap YS, Ng RC, Wong NS, Dent R, Habbal MZ, Schaeffeler E, Eichelbaum M, Schroth W, Schwab M, Brauch H (2015) 'Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer', The Pharmacogenomics Journal 15(1):84–94. doi:10.1038/tpj.2014.34, https://doi.org/10.1038/tpj.2014.34
  4. Sanchez-Spitman AB, Moes DAR, Swen JJ, Dezentjé VO, Lambrechts D, Neven P, Gelderblom H, Guchelaar HJ (2020) 'Exposure-response analysis of endoxifen serum concentrations in early-breast cancer', Cancer Chemotherapy and Pharmacology 85(6):1141–1152. doi:10.1007/s00280-020-04089-x, https://doi.org/10.1007/s00280-020-04089-x
  5. Braal CL, Jager A, Oomen-de Hoop E, Westenberg JD, Lommen KMWT, de Bruijn P, Vastbinder MB, van Rossum-Schornagel QC, Thijs-Visser MF, van Alphen RJ, Struik LEM, Zuetenhorst HJM, Mathijssen RHJ, Koolen SLW (2021) 'Therapeutic Drug Monitoring of Endoxifen for Tamoxifen Precision Dosing: Feasible in Patients with Hormone-Sensitive Breast Cancer', Clinical Pharmacokinetics 61(4):527–537. doi:10.1007/s40262-021-01077-z, https://doi.org/10.1007/s40262-021-01077-z
  6. Helland T, Alsomairy S, Lin C, Søiland H, Mellgren G, Hertz D (2021) 'Generating a Precision Endoxifen Prediction Algorithm to Advance Personalized Tamoxifen Treatment in Patients with Breast Cancer', Journal of Personalized Medicine 11(3):201. doi:10.3390/jpm11030201, https://doi.org/10.3390/jpm11030201
  7. DeCensi A, Johansson H, Helland T, Puntoni M, Macis D, Aristarco V, Caviglia S, Webber TB, Briata IM, D'Amico M, Serrano D, Guerrieri-Gonzaga A, Bifulco E, Hustad S, Søiland H, Boni L, Bonanni B, Mellgren G (2021) 'Association of CYP2D6 genotype and tamoxifen metabolites with breast cancer recurrence in a low-dose trial', npj Breast Cancer 7:34. doi:10.1038/s41523-021-00236-6, https://doi.org/10.1038/s41523-021-00236-6
  8. He W, Eriksson M, Eliasson E, Grassmann F, Bäcklund M, Gabrielson M, Hammarström M, Margolin S, Thorén L, Wengström Y, Borgquist S, Hall P, Czene K (2021) 'CYP2D6 genotype predicts tamoxifen discontinuation and drug response: a secondary analysis of the KARISMA trial', Annals of Oncology 32(10):1286–1293. doi:10.1016/j.annonc.2021.07.005, https://doi.org/10.1016/j.annonc.2021.07.005
  9. Mueller-Schoell A, Klopp-Schulze L, Michelet R, van Dyk M, Mürdter T, Schwab M, Joerger M, Huisinga W, Mikus G, Kloft C (2021) 'Simulation-Based Assessment of the Impact of Non-Adherence on Endoxifen Target Attainment in Different Tamoxifen Dosing Strategies', Pharmaceuticals 14(2):115. doi:10.3390/ph14020115, https://doi.org/10.3390/ph14020115
  10. Groenland SL, van Eerden RAG, Westerdijk K, Meertens M, Koolen SLW, Moes DJAR, de Vries N, Rosing H, Otten H, Vulink AJE, Desar IME, Imholz ALT, Gelderblom H, van Erp NP, Beijnen JH, Mathijssen RHJ, Huitema ADR, Steeghs N (2022) 'Therapeutic drug monitoring-based precision dosing of oral targeted therapies in oncology: a prospective multicenter study', Annals of Oncology 33(10):1071–1082. doi:10.1016/j.annonc.2022.06.010, https://doi.org/10.1016/j.annonc.2022.06.010
  11. Agema B, Buijs S, Sassen S, Mürdter T, Schwab M, Koch B, Jager A, van Schaik RV, Mathijssen R, Koolen S (2023) 'Toward model-informed precision dosing for tamoxifen: A population-pharmacokinetic model with a continuous CYP2D6 activity scale', Biomedicine & Pharmacotherapy 160:114369. doi:10.1016/j.biopha.2023.114369, https://doi.org/10.1016/j.biopha.2023.114369
  12. Centanni M, Reijnhout N, Thijs A, Karlsson MO, Friberg LE (2024) 'Pharmacogenetic Testing or Therapeutic Drug Monitoring: A Quantitative Framework', Clinical Pharmacokinetics 63(6):871–884. doi:10.1007/s40262-024-01382-3, https://doi.org/10.1007/s40262-024-01382-3
  13. Mc Laughlin AM, Helland T, Klima F, Koolen SLW, van Schaik RHN, Mathijssen RHJ, Neven P, Swen JJ, Guchelaar HJ, Dalenc F, White-Koning M, Michelet R, Mikus G, Schroth W, Mürdter T, Brauch H, Schwab M, Søiland H, Mellgren G, Thomas F, Kloft C, Hertz DL (2024) 'Nonlinear Mixed-Effects Model of Z-Endoxifen Concentrations in Tamoxifen-Treated Patients from the CEPAM Cohort', Clinical Pharmacology & Therapeutics 116(3):690–702. doi:10.1002/cpt.3238, https://doi.org/10.1002/cpt.3238
  14. Minichmayr I, Dreesen E, Centanni M, Wang Z, Hoffert Y, Friberg LE, Wicha S (2024) 'Model-informed precision dosing: State of the art and future perspectives', Advanced Drug Delivery Reviews 215:115421. doi:10.1016/j.addr.2024.115421, https://doi.org/10.1016/j.addr.2024.115421
  15. Stearns V, O'Neill A, Schneider BP, Skaar TC, Liu MC, Lohrisch C, Goetz MP, Vallejos CS, Sparano JA, Villa D, Silverman P, Cheema PS, Moore DF, Sledge GW Jr (2025) 'CYP2D6 activity in patients with metastatic breast cancer treated with single agent tamoxifen: results from ECOG-ACRIN E3108', Breast Cancer Research and Treatment 209(3):595–602. doi:10.1007/s10549-024-07519-z, https://doi.org/10.1007/s10549-024-07519-z
  16. Lee B, Nam SJ, Kim SW, Yu J, Chae BJ, Lee SK, Ryu JM, Lee JE, Lee SY (2025) 'Endoxifen Concentration Is Associated with Recurrence-Free Survival in Hormone-Sensitive Breast Cancer Patients', Cancer Research and Treatment 57(1):140–149. doi:10.4143/crt.2023.1285, https://doi.org/10.4143/crt.2023.1285
  17. Mürdter TE, Schroth W, Goetz MP, Tremmel R, Igel S, Schaeffeler E, Jäger S, Loibl S, Gerteis A, Pfaff L, Bechtner C, Wrobel D, Bernhöft I, Fischer I, Meisner C, Block M, Brauch H, Schwab M; German TAMENDOX Clinicians Group (2025) 'Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial', Clinical Cancer Research 31(23):4903–4911. doi:10.1158/1078-0432.CCR-25-2103, https://doi.org/10.1158/1078-0432.CCR-25-2103
  18. van Nijnatten RYM, Buijs S, Agema B, Fischer RMJ, Moghaddam-Helmantel IG, Contant C, de Jongh FD, Huijben A, Kop M, van der Padt-Pruijsten A, Zuetenhorst H, van Schaik RH, Koch BCP, Jager A, Koolen S, Mathijssen R (2025) 'Implementation of model-informed precision dosing for tamoxifen therapy in patients with breast cancer: A prospective intervention study', The Breast 79:103880. doi:10.1016/j.breast.2025.103880, https://doi.org/10.1016/j.breast.2025.103880
  19. Fox P, Balleine RL, Lee C, Gao B, Balakrishnar B, Menzies AM, Yeap SH, Ali A, Gebski V, Provan P, Coulter S, Liddle C, Hui R, Kefford R, Lynch D, Wong M, Wilcken N, Gurney H (2016) 'Dose Escalation of Tamoxifen in Patients with Low Endoxifen Level: Evidence for Therapeutic Drug Monitoring—The TADE Study', Clinical Cancer Research 22(13):3164–3171. doi:10.1158/1078-0432.CCR-15-1470, https://doi.org/10.1158/1078-0432.CCR-15-1470
  20. de Vries Schultink AHM, Dorlo TPC, Madlensky L, Pierce JP, Beijnen JH, Huitema ADR (2019) 'Prospective Evaluation of Therapeutic Drug Monitoring of Endoxifen: Feasibility of Observational and Randomized Trials', PAGE 2019 abstract 9150, www.page-meeting.org/?abstract=9150